HUNTSVILLE, Ala., May 20, 2011 /PRNewswire/ — Serina
Therapeutics, Inc., a pharmaceutical research and development
company, announced that the company was awarded a patent from the
United States Patent and Trademark Office covering its polymer
technology. The patent entitled “Polyoxazoline and
compositions comprising the same” (U.S. Patent No. 7,943,141)
covers the synthesis and composition of polyoxazolines for the
delivery of different drug molecules.
The patent represents years of groundbreaking research in the
development of safe polyoxazoline polymers for drug delivery.
It is the first of many patents that Serina has applied for.
“This patent award validates our invention and design of a
novel drug delivery platform and allows Serina the opportunity to
advance some of its proprietary ideas towards full development and
eventually commercialization,” said Dr. Michael D. Bentley, Chief
Scientific Officer and cofounder of the company. “We are now in a
position to build a strong pipeline of polymer therapeutic
Serina Therapeutics is a privately held pharmaceutical company
that develops novel polymer therapeutics based on its proprietary
polyoxazoline (POZ) technology platforms. The founders and
managers of Serina were formerly the key principals of Shearwater
Polymers, a company that enabled nine approved polyethylene glycol
(PEG) products for various pharmaceutical partners. Besides
developing its own pipeline of pharmaceutical products, Serina is
also partnering its technology with pharmaceutical companies to
develop high value products addressing unmet clinical needs.
For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com
Media Contact: Karen Petersen, 256-327-9434